On 1 July 2026, the Health Sciences Authority (HSA) invited feedback on its proposed regulatory framework for Complementary Health Products (CHP). CHP are self-care health products with a long history of safe use — and are intended for supporting or enhancing general health or alleviating symptoms of minor conditions that consumers can manage themselves. CHP include health supplements, traditional medicines (excluding Traditional Chinese Medicines), homeopathic medicines, medicated oils, balms, plasters, and topical antiseptics. The consultation period runs from 1 July 2026 to 29 July 2026.

The regulatory controls for various types of health products under the Medicines Act 1975 (“MA”), including CHP, are being moved to the under the Health Products Act 2007 ("HPA") in phases.

CHP are currently regulated with a light touch approach under the MA given their inherently lower risk safety profile and health claims. CHP are not subject to pre-market product evaluation and licensing of manufacturers, importers and suppliers. There are relevant safety and quality requirements for CHP, and post-market surveillance to monitor the safety and quality of marketed CHP includes sampling and testing, and monitoring of adverse events reported by healthcare professionals.

HSA intends to port over the regulatory controls for the remaining medicinal products that fall under the scope of CHP from the MA to the HPA by the end of 2028. 

The proposed regulatory framework for CHP under the HPA is intended to safeguard public health, strengthen regulatory oversight, support industry innovation, and ensure consumer protection through mandatory product traceability.

The proposed regulatory framework for CHP will be implemented in phases, beginning in the third quarter of 2028, where the proposed requirements for record keeping, safety reporting and advertisement controls will be implemented. A 2-year grace period will be provided for the implementation of product notification and other new requirements, to allow businesses sufficient time to align their existing products and processes with the new requirements. The full implementation for all requirements is targeted for the third quarter of 2030.

Companies dealing with CHP should closely monitor the regulatory developments to ensure that they are in a position to comply with any new or expanded regulatory requirements.

© 2026 Baker & McKenzie. Wong & Leow. All rights reserved. Baker & McKenzie. Wong & Leow is incorporated with limited liability and is a member firm of Baker & McKenzie International, a global law firm with member law firms around the world. In accordance with the common terminology used in professional service organizations, reference to a "principal" means a person who is a partner, or equivalent, in such a law firm. Similarly, reference to an "office" means an office of any such law firm. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.